Research programme: antibody therapeutics - Numab/Intarcia

Drug Profile

Research programme: antibody therapeutics - Numab/Intarcia

Alternative Names: Autoimmune disorders therapeutics - Numab/Intarcia; Diabetes therapeutics - Numab/Intarcia; ND 003; ND 007; Obesity therapeutics - Numab/Intarcia

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Numab
  • Developer Intarcia Therapeutics; Numab
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action CD3 antigen inhibitors; Interleukin 5 receptor antagonists; Th17 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Asthma; Diabetes mellitus; Inflammation; Obesity

Most Recent Events

  • 14 Sep 2017 Preclinical trials in Autoimmune disorders in Switzerland (unspecified route), before September 2017
  • 16 Apr 2015 Early research in Autoimmune disorders in Switzerland (unspecified route)
  • 19 Mar 2015 Early research in Diabetes mellitus in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top